Trade

with

Idera Pharmaceuticals Inc
(NASDAQ: IDRA)
AdChoices
2.38
+0.08
+3.48%
After Hours :
2.38
0.00
0.00%

Open

2.27

Previous Close

2.30

Volume (Avg)

662.87k (817.74k)

Day's Range

2.26-2.39

52Wk Range

1.55-6.87

Market Cap.

199.37M

Dividend Rate ( Yield )

-

Beta

2.71

Shares Outstanding

83.77M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 47.00k

    • Net Income

    • -18.23M

    • Market Cap.

    • 199.37M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -55,686.54

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 2.71

    • Forward P/E

    • -

    • Price/Sales

    • 3,333.33

    • Price/Book Value

    • 3.64

    • Price/Cash flow

    • -6.46

      • EBITDA

      • -18.03M

      • Return on Capital %

      • -69.34

      • Return on Equity %

      • -100.43

      • Return on Assets %

      • -69.34

      • Book Value/Share

      • 0.65

      • Shares Outstanding

      • 83.77M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • 4.00

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 31.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -71.80

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -54,032.69

            • 39.38

            • Net Profit Margin

            • -55,686.54

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -24,290.90

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -28,485.50

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 10.34

              • 2.92

              • Quick Ratio

              • 10.20

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.22

              • 2.21

              • Book Value/Share

              • 0.65

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -5.11

                • 196.08

                • P/E Ratio 5-Year High

                • -18.85

                • 634.30

                • P/E Ratio 5-Year Low

                • -0.43

                • 124.82

                • Price/Sales Ratio

                • 2,500.00

                • 9.12

                • Price/Book Value

                • 3.37

                • 8.26

                • Price/Cash Flow Ratio

                • -6.46

                • 47.39

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -100.43

                        (-368.90)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -69.34

                        (-66.20)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -100.43

                        (-368.90)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • -

                      • 1.48

                      • Asset Turnover

                      • 0.00

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -18.17M
                      Operating Margin
                      -38,657.45
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -6.46
                      Ownership

                      Institutional Ownership

                      33.86%

                      Top 10 Institutions

                      28.25%

                      Mutual Fund Ownership

                      10.12%

                      Float

                      80.53%

                      5% / Insider Ownership

                      1.87%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Fidelity Special Situations Class

                      •  

                        1,368,049

                      • 0.00

                      • 1.74

                      • Vanguard Total Stock Mkt Idx

                      •  

                        1,158,303

                      • 0.00

                      • 1.38

                      • iShares Russell 2000 (AU)

                      •  

                        927,174

                      • -1.02

                      • 1.11

                      • Vanguard Extended Market Index Fund

                      •  

                        777,281

                      • 0.00

                      • 0.93

                      • iShares Russell 2000 Growth

                      •  

                        384,557

                      • -2.73

                      • 0.46

                      • DFA U.S. Micro Cap Portfolio

                      •  

                        288,928

                      • 0.00

                      • 0.34

                      • Fidelity Spartan® Extended Mkt Indx Fd

                      •  

                        239,487

                      • 0.00

                      • 0.29

                      • AST FI Pyramis® Quant Asset Allc Port

                      •  

                        208,580

                      • 0.00

                      • 0.25

                      • Vanguard Instl Total Stock Market Index

                      •  

                        206,802

                      • 0.00

                      • 0.25

                      • CREF Stock

                      •  

                        202,813

                      • -1.66

                      • 0.24

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Broadfin Capital, LLC

                      •  

                        3,525,700

                      • +10.15%

                      • 4.21

                      • Natixis

                      •  

                        3,148,916

                      • -0.01%

                      • 3.76

                      • Pyramis Global Advisors, LLC

                      •  

                        2,331,241

                      • +11.17%

                      • 2.78

                      • Vanguard Group, Inc.

                      •  

                        2,113,028

                      • +17.03%

                      • 2.52

                      • Baker Bros Advisors LLC

                      •  

                        1,613,076

                      • 0.00%

                      • 1.93

                      • Fidelity Management and Research Company

                      •  

                        1,368,049

                      • +60.95%

                      • 1.63

                      • Millennium Management LLC

                      •  

                        1,048,544

                      • -60.15%

                      • 1.25

                      • Dimensional Fund Advisors, Inc.

                      •  

                        968,484

                      • -0.33%

                      • 1.16

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Distressed

                      Style

                      Small Core

                      Idera Pharmaceuticals, Inc. was incorporated in Delaware on May 25, 1989. The Company is a clinical stage biotechnology company engaged in the discovery and development of novel synthetic DNA- and RNA- based drug candidates. It is de...moreveloping drug candidates that are designed to modulate immune responses mediated through Toll-like Receptors, or TLRs. The Company is also evaluating gene silencing oligonucleotides, or GSOs, which inhibit the production of disease-associated proteins by targeting RNA. TLRs are specific receptors present in immune system cells. Using a chemistry-based approach, the Company has created synthetic DNA- and RNA-based compounds that are targeted to TLRs 3, 7, 8, and 9. A TLR agonist is a compound that stimulates an immune response through the targeted TLR. A TLR antagonist is...more a compound that blocks activation of an immune response through the targeted TLR. Drug candidates are compounds that the Company is developing and that have not been approved for any commercial use. The Company is focusing its internal development efforts on TLR-targeted clinical candidates for autoimmune and inflammatory diseases and cancer, and on the advancement of its GSO technology platform. The Company is developing IMO-3100, an antagonist of TLR7 and TLR9, for the treatment of psoriasis. It is conducting nonclinical studies of IMO-8400 to support the submission of an Investigational New Drug Application, or IND, for IMO-8400. Its GSOs are single-stranded RNA or DNA constructs that are complementary to targeted mRNA sequences of therapeutic interest. In preclinical studies, the Company’s GSOs has inhibited in vivo gene expression without requiring a delivery enhancement technology. In addition to its clinical programs in autoimmune and inflammatory diseases and in cancer, the Company has identified TLR drug candidates for applications in the treatment of infectious diseases, respiratory diseases and hematological malignancies, and TLR3 agonists for use as vaccine adjuvants. The principal competitor developing TLR-targeted compounds for autoimmune diseases is Dynavax Technologies Corporation, or Dynavax, with its collaborator, GlaxoSmithKline plc, or GlaxoSmithKline. The testing, manufacturing, labeling, advertising, promotion, export, and marketing of its products are subject to extensive regulation by governmental authorities in Europe, the United States, and elsewhere throughout the world.lessless

                      Key People

                      Dr. Sudhir Agrawal,D.Phil.

                      CEO/Director/President

                      James A. Geraghty

                      Chairman of the Board/Director

                      Youssef El-Zein

                      Director/Vice Chairman of the Board

                      Mr. Louis J. Arcudi,III

                      CFO/Chief Accounting Officer/Secretary/Senior VP, Divisional/Treasurer

                      Dr. Timothy M. Sullivan,PhD

                      Vice President, Divisional

                      • Idera Pharmaceuticals Inc

                      • 167 Sidney Street

                      • Cambridge, MA 02139

                      • USA.Map

                      • Phone: +1 617 679-5500

                      • Fax: +1 617 679-5592

                      • iderapharma.com

                      Incorporated

                      1989

                      Employees

                      18

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: